Oppenheimer analyst Leland Gershell raised the firm’s price target on Argenx (ARGX) to $704 from $675 and keeps an Outperform rating on the shares. The firm notes Q4 sales of $737M came in as pre-announced, and Vyvgart’s utilization continues to grow through prescriber breadth and depth. Oppenheimer says it lacks clarity on CIDP revenue contribution, but believes this primarily drove the beat.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $701 from $696 at Citizens JMP
- Argenx price target raised to $741 from $723 at Wells Fargo
- Argenx price target raised to $720 from $717 at H.C. Wainwright
- Argenx Se: Promising Outlook with Vyvgart Momentum and Pipeline Expansion Justifies Buy Rating
- Argenx Reports Strong 2024 Financial Results and Strategic Growth